On December 21, 2021 Biomea Fusion, Inc. ("Biomea") (Nasdaq: BMEA), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel irreversible small molecules to treat and improve the lives of patients with genetically defined cancers, reported that it will present at the upcoming virtual 40th Annual J.P. Morgan Healthcare Conference (Press release, Biomea Fusion, DEC 21, 2021, View Source [SID1234597523]). Thomas Butler, Chief Executive Officer and Chairman of the Board, is scheduled to present on Wednesday, January 12, 2022, at 12:00pm Pacific Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live audio webcast of the presentation can be accessed at www.biomeafusion.com and will be available for 30 days following the presentation.